Fig. 2From: Menacalc, a quantitative method of metastasis assessment, as a prognostic marker for axillary node-negative breast cancerKaplan-Meier analysis of Menacalc for ANN tumors subclassified by immunohistochemical subtype: HER2 amplified (n = 20, top left), basal (n = 48, top right) and luminal (n = 165, bottom left). In brackets is the total number of patients followed by the number of patient deaths for each groupBack to article page